Date: 2017-07-07
Type of information: Resignation
Compound:
Company: Relief Therapeutics (Switzerland)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details:
- • On July 7, 2017, Relief Therapeutics announced that Dr. David A. Lowe has resigned from his position of member of the Board of Directors. The company is developing aviptadil for the treatment of sarcoidosis (to enter Phase III) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (to enter Phase II). This drug is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, and has been the subject of multiple clinical trials.
Financial terms:
Latest news:
Is general: Yes
